Shots:
- The P-IIb dose-ranging study evaluates the antiretroviral activity, tolerability & safety of islatravir (0.25/0.75/2.25mg) + doravirine vs DOR/3TC/TDF in a ratio (1:1:1:1) in adults with HIV-1
- The results showed that islatravir + doravirine continued to maintain viral suppression @144wks.; 72.2% of the combined groups had HIV-RNA levels <50 copies/mL similar to 77.4% of DOR/3TC/TDF group.; treatment discontinuations due to drug-related AEs (2.2% & 3.2%) before 48wks. The results were consistent with the 96wks. results in 0.75mg dose group
- Islatravir is currently being evaluated in multiple dosing regimens for HIV-1 as monothx. or in combination with other antiretroviral agents
Click here to read full press release/ article | Ref: Merck | Image: Fortune
The post Merck Presents Results of Islatravir + Doravirine in P-IIb Clinical Trial for the Treatment of HIV-1 at EACS 2021 first appeared on PharmaShots.
